Congressional Committee Orders DEA to Crack Down on Unregulated Cannabis Products

A key House committee is poised to step up federal action against unregulated cannabinoid products, citing concerns over consumer safety. On Wednesday, the House Appropriations Committee will review a fiscal year 2027 spending bill and an attached report that explicitly directs the Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA) to target products containing intoxicating cannabinoids that are not federally regulated. This move reflects growing anxiety in Congress over the rapid spread of ingestible, inhalable, and topical cannabinoid goods that may not meet legal definitions or safety standards

The committee's report outlines specific instructions for the DEA to coordinate with the FDA's Office of Inspections and Investigations. "The Committee directs the DEA, in coordination with the FDA Office of Inspections and Investigations, to take appropriate enforcement actions against those whose products threaten consumer safety and fail to meet the statutory definition of section 10113 of Public Law 115–334 and section 781 of Public Law 119–37," the report states. The agencies are also required to submit a report on enforcement efforts and resource needs within 90 days after the bill's enactment

Although the directive avoids directly mentioning 'hemp,' it references laws governing the crop and appears to address the influx of products derived from hemp that became legal after the 2018 Farm Bill. However, Congress has since advanced new legislation, signed by President Trump, that will effectively recriminalize hemp-derived THC products starting in November. This shifting legal landscape has left manufacturers and retailers scrambling to interpret evolving federal guidance and prepare for stricter enforcement

Beyond cannabinoids, the appropriations report calls for the Department of Justice to investigate money laundering schemes linked to Chinese-connected illicit marijuana operations in the United States. The committee instructs the DOJ to use anti-money laundering program funds to pursue these cases, stating, "The Committee directs the Department to utilize funds directed to anti-money laundering programs to investigate potential money laundering schemes involving CCP-connected marijuana businesses and entities providing financial services to these businesses." Additionally, $8.5 million has been allocated to the Bureau of Prisons for a pilot program to monitor drug use and infectious diseases through wastewater surveillance at federal correctional facilities

The spending bill also maintains protections for state medical cannabis programs, upholding a rider that has been in place since 2014 to shield these programs from federal interference. At the same time, it blocks federal officials from advancing cannabis rescheduling efforts. These measures come as Congress debates broader reforms, including a recent House-passed Farm Bill with provisions for industrial hemp producers and a proposed amendment to allow VA doctors to recommend medical marijuana to veterans

From the OG Lab newsroom perspective, this new directive underscores intensifying federal scrutiny on the cannabis industry, particularly around products that fall outside established regulatory frameworks. The push for enforcement and reporting requirements signals a shift toward tighter oversight, with significant implications for producers, retailers, and consumers. As the legal environment continues to evolve, industry stakeholders will need to stay alert to further changes in enforcement priorities and federal policy